GRAIL falls 13.0% after disclosure of CEO share sale amid weak session

What happened

GRAIL (GRAL) fell 13.0% to close at $117.81 on October 16, 2026, after disclosure of a CEO share sale. The stock opened 1.1% below the previous close and traded at 0.9 times its 20-day average volume as the S&P 500 fell 1.1% and the healthcare sector median fell 3.1% on the day. The move was far larger than the market and sector and was driven mainly by company-specific news.

How big was the move

The decline was 2.0 times a typical daily move for this stock and was 10.0 percentage points worse than the sector median, marking a large, mostly company-specific move. The stock has a beta of 2.72, so it tends to move more than the market; over the last five sessions the stock fell 16.2%. In the past five years the stock had 9 sessions with a decline of at least 13.0%. Twenty trading days later the median result was a decline of 6.2%, and 4 of 9 were higher. Those longer-run outcomes suggest that big one-day drops have often been followed by further weakness, though a minority of such episodes recovered.

The technical picture

Technically the stock sat 10.4% below its 20-day moving average while remaining 19.6% above its 50-day moving average and 54.9% above its 200-day average. The 50-day average is above the 200-day average, a sign of an established uptrend, and the stock had spent 42 consecutive trading days above its 200-day average. The 14-day Relative Strength Index was 48, in a neutral range between 30 and 70. The share price was 29.2% below its 52-week high despite strong recent gains: it rose 47.4% over one month, 71.0% over three months and 56.0% over one year. Volatility was elevated at 103% annualized over 60 days, higher than 59% of its own readings over five years, a pattern consistent with sharp moves in both directions.

Fundamentals and valuation

Over the four quarters through June 30, 2026, GRAIL reported revenue of $165.3 million, up 23.1% from a year earlier and accelerating from a prior quarter growth of 19.4%. The company reported diluted earnings per share of $-9.75 for that period. Gross margin stood at 10.8%, down from 56.5% a year earlier, while reported operating margin was 338.4% compared with 471.3% a year earlier. Free-cash-flow margin was 178.7% and return on invested capital was 14.9%. Share count increased by 23.0% over one year. Market value stood at $5.26 billion and free-cash-flow yield was 4.9%.

Those figures underline a contrast between rapid top-line expansion and unusual profitability and margin swings. Revenue growth and a high return on invested capital support the strong Growth score, but collapsing gross margin and large changes in operating and free-cash-flow margins help explain low Quality and Stability scores.

Earnings and analyst expectations

GRAIL last reported on August 5, 2026, with earnings per share of $-2.56 against $-2.66 expected, 3.8% above estimates. The company has beaten estimates for four consecutive quarters, with average surprise over the last four reports of 18.6% above estimates, and typical two-day reactions after recent reports saw the stock rise 1.5%. The next report is scheduled for November 11, 2026.

Eight analysts covered the stock, with a consensus rating of Buy and 62% of ratings at Buy. The consensus price target was $106.14, which was 9.9% below the October 16, 2026, closing price of $117.81. The gap between the consensus target and the share price highlights differing views about how sustainably the company can convert recent revenue growth into stable margins.

What to watch

• October 15, 2026: CEO Joshua Ofman sold 20,000 shares at an average price of $136.85, generating $2,737,000 in proceeds; after the sale he held 342,271 shares.
• November 11, 2026: next scheduled earnings report date.
• Consensus price target $106.14, which is 9.9% below the October 16, 2026, closing price of $117.81.
• Recent trading: stock rose 47.4% over one month and is 29.2% below its 52-week high.